Rupak Shivakoti, PhD, MSPH

CRS:

BJMC

Role:

Investigators

Position:

Investigator

Rupak Shivakoti, PhD, MSPH, is an Assistant Professor of Epidemiology at Columbia University Mailman School of Public Health, and a member of the faculty at the Johns Hopkins Center for Clinical Global Health Education. His formal training is in immunology, infectious diseases, and epidemiology.
 
Dr. Shivakoti’s primary research interest focuses on the central role of inflammation in HIV and TB outcomes, both in adult and maternal-infant populations. In addition, he is interested in the relationship of nutrition and gut microbiome with inflammation and health outcomes. He is the PI of NIH-funded projects related to these topics and conducted in diverse international settings, with a strong focus in India. More about Dr. Shivakoti's work can be found in the tabs below.
 
After completing his undergraduate degree in biology from DePauw University, Dr. Shivakoti received a MSPH in international health and a PhD in molecular microbiology and immunology from the Johns Hopkins Bloomberg School of Public Health. His PhD thesis, under the direction of Dr. Diane Griffin, focused on the innate and adaptive immune responses to the measles virus and measles vaccine. He completed his post-doctoral fellowship at JHU CCGHE with Dr. Amita Gupta serving as his mentor.

  • Investigator, NWCS 319, parent study A5175
  • Study Chair, NWCS 448, parent study A5331
  • Member, End-Organ Disease and Inflammation Transformative Science Group (Dec 2017-Nov 2019)

Categories

Leadership Committees
CRS
Roles

Clinical Trials

A5384: A Phase II, Randomized, Open-Label Trial of a...

Study Description A5384 is a trial for people who have or might have tuberculous meningitis (TBM). TBM is an infectious disease...

Read More

P2010: Phase III Study of the Virologic Efficacy and Safety...

IMPAACT 2010 is a Phase III, three-arm, randomized, open-label study of HIV-1-infected pregnant women initiating either a...

Read More

A5273: Multicenter Study of Options for Second-Line...

The study is being done with people who are taking their first anti-HIV drug regimen (including an Non-Nucleoside Reverse...

Read More

A5274: REMEMBER, Reducing Early Mortality and Early...

This study is being done in people who are starting HIV treatment and who live in areas where the TB infection rate is high. The...

Read More

A5329: Interferon –Free Therapy for Chronic Hepatitis C...

A5329 is a study for people who are infected with both HIV and the Hepatitis C virus (HCV) and have never taken Hepatitis C...

Read More